NMN oral intake shown safe and well metabolised for the first time – Oriental Yeast funded trial
A trial involving healthy Japanese men revealed for the first time that a single dose of nicotinamide mononucleotide (NMN) is safe for consumption and is effectively metabolised by the body.
The study, published in Endocrine Journal, was conducted by researchers from the Keio University School of Medicine and a number of industry research labs.
NMN is an intermediate compound of nicotinamide adenine dinucleotide (NAD+). Administration of NMN has been shown to mitigate ageing-related dysfunctions.
The researchers believed that this is the first human study to examine the safety of NMN oral administration.
